Univercells, founded in 2013 and headquartered in Belgium, delivers groundbreaking end-to-end biomanufacturing solutions designed to make biologics, vaccines, and viral therapies more accessible and affordable worldwide.

Their innovative platforms—such as scale‑X single-use bioreactors, NevoLine™ upstream systems, Ntensify RNA production, and CDMO services—combine perfusion cell culture, integrated filtration, and continuous processing to slash manufacturing footprint, capital expenditures (up to 75%), and cost of goods (up to 90%) 

Univercells partners with global health leaders, biotech firms, and governments to deploy modular, scalable biologics capacity—including viral vector vaccines and gene therapies—in emerging and established markets. Backed by strategic investments from the Bill & Melinda Gates Foundation, Takeda Ventures, and acquired by Donaldson in 2023, Univercells continues to lead in compact, affordable, and sustainable bioproduction innovation